Titan Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 4/6

Titan Pharmaceuticals has a total shareholder equity of $4.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $4.4M and $356.0K respectively.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	n/a
현금	US$4.09m
주식	US$3.99m
총 부채	US$356.00k
총 자산	US$4.35m

최근 재무 상태 업데이트

Is Titan Pharmaceuticals (NASDAQ:TTNP) In A Good Position To Invest In Growth?

Jul 10

Recent updates

재무 상태 분석

단기부채: TTNP's short term assets ($4.4M) exceed its short term liabilities ($356.0K).

장기 부채: TTNP has no long term liabilities.

부채 대 자본 내역 및 분석

부채 수준: TTNP is debt free.

부채 감소: TTNP currently has no debt however we can't compare to 5 years ago as we have no data for that period.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: TTNP has less than a year of cash runway based on its current free cash flow.

예측 현금 활주로: TTNP has less than a year of cash runway if free cash flow continues to grow at historical rates of 12.3% each year.

Titan Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

Titan Pharmaceuticals, Inc. announced delayed 10-Q filing

Titan Pharmaceuticals Receives Extension Notice from the Listing Qualifications Department of the Nasdaq Notifying the Company an Additional 180-Day Period, or Until October 2, 2023 to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Is Titan Pharmaceuticals (NASDAQ:TTNP) In A Good Position To Invest In Growth?

Titan Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Titan Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Recent updates

Titan Pharmaceuticals, Inc. Announces Resignation of Dato’ Seow Gim Shen as Chairman of the Board

Ke Sdn. Bhd. entered into an agreement to acquire Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $21.6 million in a reverse merger transaction.

Titan Pharmaceuticals, Inc. announced delayed 10-Q filing

Titan Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $11 million.

Titan Pharmaceuticals, Inc. Announces Resignation of Brian Crowley as Senior Vice President, Finance and Administration, Effective February 2, 2024

Third quarter 2023 earnings released: US$0.023 loss per share (vs US$0.18 loss in 3Q 2022)

High number of new and inexperienced directors

Titan Pharmaceuticals, Inc. Announces Board Resignations

Titan Pharmaceuticals, Inc. announced that it expects to receive $9.5 million in funding from Sire Group Ltd

Second quarter 2023 earnings released: US$0.11 loss per share (vs US$0.18 loss in 2Q 2022)

Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $52 million.

Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $52 million.

Titan Pharmaceuticals, Inc. Announces Board Changes

New major risk - Market cap size

Titan Pharmaceuticals Receives Extension Notice from the Listing Qualifications Department of the Nasdaq Notifying the Company an Additional 180-Day Period, or Until October 2, 2023 to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.24 loss in 1Q 2022)

Principal Executive Officer recently bought US$56k worth of stock

Titan Pharmaceuticals, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective August 16, 2022

Less than half of directors are independent

Titan Pharmaceuticals, Inc. Announces Management Changes

Less than half of directors are independent

Titan Pharmaceuticals Announces Executive Changes

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.17 loss in 2Q 2021)

Activist Investing LLC Provides Information to the Shareholders

Is Titan Pharmaceuticals (NASDAQ:TTNP) In A Good Position To Invest In Growth?

Insider recently bought US$1.7m worth of stock

David E Lazar Sends a Letter to Titan Pharmaceuticals Inc

Titan Pharmaceuticals, Inc. Announces Fda Clearance of Ind Application for Nalmefene Implant

Insider recently bought US$348k worth of stock

First quarter 2022 earnings released: US$0.24 loss per share (vs US$0.28 loss in 1Q 2021)

Titan Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Insider recently bought US$157k worth of stock

Full year 2021 earnings released: US$0.90 loss per share (vs US$1.96 loss in FY 2020)

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.45 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$1.47 loss in 2Q 2020)

Titan Pharmaceuticals, Inc. Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus

First quarter 2021 earnings released: US$0.28 loss per share (vs US$2.03 loss in 1Q 2020)

New 90-day low: US$2.88

Titan Pharmaceuticals, Inc. Announces Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with Its Jt-09 Proneura® Development Program

Titan Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Titan Pharma regains Nasdaq listing compliance

Titan Pharmaceuticals announces 1-for-30 reverse stock split

Titan Pharmaceuticals, Inc., Annual General Meeting, Dec 30, 2020

Titan Pharmaceuticals EPS misses by $0.01, beats on revenue

Titan Pharma closes debt settlement and JT-09 acquisition

Titan Pharmaceuticals, Inc. has completed a Composite Units Offering in the amount of $11.44275 million.

Titan Pharma to raise $8M in stock offering

Titan Pharmaceuticals, Inc. Announces Executive Changes

Titan Pharmaceuticals, Inc. to Report Q3, 2019 Results on Nov 14, 2019

Analysts update estimates

New 90-day low - US$0.27

Earnings released

Titan Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 14, 2020

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기